Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + Laser Ablation in Recurrent Malignant Gliomas
NCT02311582Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2015
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in malignant glioma and glioblastoma multiforme (GBM) (5 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose and Progression-free Survival. Started Aug 2015; status: completed.
02
Drugs
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02311582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311582.